Rheumatic manifestations of skin disease

Current Opinion in Rheumatology

Volumn 22, Issue 1, 2010, Pages 78-84

  Clarke, Jennie T ^a   Werth, Victoria P ^b,c  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Philadelphia VA Medical Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cutaneous lupus erythematosus; Dermatomyositis; Rheumatoid arthritis; Scleroderma

Indexed keywords

ANTIMALARIAL AGENT; AROMATASE INHIBITOR; BETA INTERFERON; BETA1A INTERFERON; BOSENTAN; CALCINEURIN INHIBITOR; CAPECITABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; HYDROXYUREA; ILOPROST; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LEFLUNOMIDE; LENALIDOMIDE; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; RECOMBINANT RELAXIN; RITUXIMAB; SERTRALINE; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; INCIDENCE; INJECTION SITE REACTION; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RISK FACTOR; SCLERODERMA; SENSORY NEUROPATHY; SKIN DISEASE; SKIN INFLAMMATION; SKIN LUPUS ERYTHEMATOSUS; SKIN ULCER; SMOKING; SYMPTOM; SYSTEMIC SCLEROSIS; VASCULITIS;

CYTOKINES; DERMATOMYOSITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; RAYNAUD DISEASE; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 73649112427     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328333b9e2     Document Type: Review

References (74)

1. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4:471-475.
2. Werth VP. Clinical manifestations of cutaneous lupus erythematosus. J Autoimmun 2005; 4:296-302.
3. Albrecht JA, Braverman IM, Callen JP, et al. Dermatology position paper on the revision of the 1982 ACR criteria for SLE. Lupus 2004; 13: 839-849.
4. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996; 135:355-362.
5. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001:CD002954.
6. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous LE Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125:889-894.
7. Kreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007; 156:1321-1327.
8. Callen JP. Clinically relevant information about cutaneous lupus erythematosus. Arch Dermatol 2009; 145:316-319.
9. Hemmati I, Otberg N, Martinka M, et al. Discoid lupus erythematosus presenting with cysts, comedones, and cicatricial alopecia on the scalp. J Am Acad Dermatol 2009; 60:1070-1072.
10. Lehtinen DA, Harvey S, Mulcahy MJ, et al. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. J Biol Chem 2008; 283:31649-31656.
11. Nico MM, Vilela MA, Rivitti EA, Lourenco SV. Oral lesions in lupus erythematosus: Correlation with cutaneous lesions. Eur J Dermatol 2008; 18:376-381.
12. Nuzum-Keim AD, Sontheimer RD. Ultraviolet light output of compact fluorescent lamps: Comparison to conventional incandescent and halogen residential lighting sources. Lupus 2009; 18:556-560.
13. Klein RS, Werth VP, Dowdy JC, Sayre RM. Analysis of compact fluorescent lights for use by patients with photosensitive conditions. Photochem Photobiol 2009; 85:1004-1010.
14. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: A paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301: 65-70.
15. Bonilla-Martinez Z, Albrecht J, Taylor L, et al. The CLASI is a useful clinical instrument to separately follow activity and damage during therapy of cutaneous lupus erythematosus. Arch Dermatol 2008; 144: 173-180.
16. Krathen MS, Dunham J, Gaines E, et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity index (CLASI) expansion for rheumatology and dermatology. Arthr Care Res 2008; 59:338-344.
17. Kuhn A, Kuehn E, Meuth AM, et al. Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2009; 8:702-712.
18. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: A population-based study. Arch Dermatol 2009; 145:249-253.
19. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009; 145:255-260.
20. Koskenmies S, Jarvinen TM, Onkamo P, et al. Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus 2008; 17:337-347.
21. Popovic K, Wahren-Herlenius M, Nyberg F. Clinical follow-up of 102 anti-Ro/ SSA-positive patients with dermatological manifestations. Acta Derm Venereol 2008; 88:370-375.
22. Sampaio MC, de Oliveira ZN, Machado MC, et al. Discoid lupus erythematosus in children: A retrospective study of 34 patients. Pediatr Dermatol 2008; 25:163-167.
23. Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: Impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2008; 24:260-267.
24. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: An evidence-based evaluation. Eur J Clin Pharmacol 2008; 64:337-341.
25. Kreuter A, Gaifullina R, Tigges C, et al. Lupus erythematosus tumidus: Response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol 2009; 145:244-248.
26. Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol Arch Dermatol 2009; 145:303-306.
27. Erceg A, Bovenschen HJ, van de Kerkhof PC, et al. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol 2009; 60:626-632.
28. Zara G, Ermani M, Rondinone R, et al. Thalidomide and sensory neurotoxicity: A neurophysiological study. J Neurol Neurosurg Psychiatry 2008; 79:1258-1261.
29. Smith ES, Hallman JR, DeLuca AM, et al. Dermatomyositis: A clinicopathological study of 40 patients. Am J Dermatopathol 2009; 31:61-67.
30. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: A review of case reports. J Am Acad Dermatol 2008; 59:872-880.
31. Dourmishev LA, Dourmishev AL. Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations. Expert Opin Drug Saf 2008; 7:421-433.
32. Somani AK, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008; 144:1341-1349.
33. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67:1670-1677.
34. Klein RQ, Bangert CC, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887-894.
35. Huber AM, Lachenbruch PA, Dugan EM, et al. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: Results using abbreviated formats. Arthritis Rheum 2008; 59:352-356.
36. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44:2828-2835.
37. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43:2445-2454.
38. Perera A, Fertig N, Lucas M, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with antitopoisomerase I antibody. Arthritis Rheum 2007; 56:2740-2746.
39. Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. Arthritis Rheum 2007; 56:2422-2431.
40. Hanitsch LG, Burmester GR, Witt C, et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations: An analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxf) 2009; 48:70-73.
41. Furst D, Khanna D, Matucci-Cerinic M, et al. Systemic sclerosis: Continuing progress in developing clinical measures of response. J Rheumatol 2007; 34:1194-1200.
42. Czirjak L, Nagy Z, Aringer M, et al. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007; 66:966-969.
43. Czirjak L, Foeldvari I, Muller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology (Oxf) 2008; 47 (Suppl 5):v44-v45.
44. Gazi H, Pope JE, Clements P, et al. Outcome measurements in scleroderma: Results from a delphi exercise. J Rheumatol 2007; 34:501-509.
45. Morita A, Kobayashi K, Isomura I, et al. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43:670-674.
46. Sakakibara N, Sugano S, Morita A. Ultrastructural changes induced in cutaneous collagen by ultraviolet-A1 and psoralen plus ultraviolet A therapy in systemic sclerosis. J Dermatol 2008; 35:63-69.
47. Rose RF, Turner D, Goodfield MJ, Goulden V. Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis. Photodermatol Photoimmunol Photomed 2009; 25:153-155.
48. Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol 2008; 158:1063-1068.
49. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose Dpenicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42:1194-1203.
50. Vanthuyne M, Blockmans D, Westhovens R, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25:287-292.
51. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study. Rheumatology (Oxf) 2009 [Epub ahead of print].
52. Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60:578-583.
53. Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60:1102-1111.
54. Denton CP, Merkel PA, Furst DE, et al. Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56:323-333.
55. Kawald A, Burmester GR, Huscher D, et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: A randomized, open, single-center study. J Rheumatol 2008; 35:1830-1837.
56. Sebastiani M, Manfredi A, Colaci M, et al. Capillaroscopic skin ulcer risk index: A new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 2009; 61:688-694.
57. Hemmatazad H, Rodrigues HM, Maurer B, et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum 2009; 60:1519-1529.
58. Ikawa Y, Ng PS, Endo K, et al. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-betainduced mouse fibrosis. J Cell Physiol 2008; 216:680-687.
59. Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009; 60:584-591.
60. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311-322.
61. Rozin A, Yigla M, Guralnik L, et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006; 25:384-388.
62. Chao J, Parker BA, Zvaifler NJ. Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis. J Rheumatol 2009; 36:1087-1088.
63. Sayah A, English JC. Rheumatoid arthritis: A review of the cutaneous manifestations. J Am Acad Dermatol 2005; 53:191-209.
64. Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21:35-40.
65. Puechal X, Miceli-Richard C, Mejjad O, et al. Antitumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008; 67:880-884.
66. Kawakami T, Yamazaki M, Kawasaki K, et al. Therapeutic effect of argatroban on rheumatoid vasculitis with antiphosphatidylserine-prothrombin complex antibody. Arch Dermatol 2008; 144:1075-1076.
67. Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994; 130:1278-1283.
68. Kawachi Y, Nakamura Y, Yoh K, et al. Rheumatoid papules successfully treated with oral tacrolimus. J Eur Acad Dermatol Venereol 2008; 22:241-242.
69. Kreuter A, Gambichler T, Altmeyer P. Infliximab therapy for interstitial granulomatous dermatitis. J Eur Acad Dermatol Venereol 2007; 21:251-252.
70. Hu S, Cohen D, Murphy G, et al. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis 2008; 81:336-338.
71. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006; 142:198-202.
72. Fiorentino DF. The Yin and Yang of TNF-alpha inhibition. Arch Dermatol 2007; 143:233-236.
73. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitorinduced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9:1-14.
74. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143:223-231.